Regulation of Cell-Mediated Immunity in Leishmaniasis

  • F. Y. Liew
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 155)

Abstract

Leishmaniasis is caused by species of the intracellular protozoan parasite belonging to the genus Leishmania. There are three main categories of leishmaniasis: cutaneous leishmaniasis (oriental sore), mucocutaneous leishmaniasis (espundia) and visceral leishmaniasis (kala azar). An incidence rate of 400 000 new cases per year has been reported, and the world wide prevalence of leishmaniasis is estimated to be 12 million cases (MODABBER 1987). Visceral leishmaniasis is fatal if not treated. The last epidemic of leishmaniasis that occurred in India in 1977-1978 caused an estimated 20 000 deaths. Most forms of leishmaniasis are zoonotic, and humans are infected only secondarily. Animal reservoirs of species pathogenic to man include the sloth, dog and rodent. The parasites are transmitted by female sandflies, and the flagellated promastigotes develop in the gut of the sandfly and in cell-free cultures. Transformation into the amastigote stage occurs within the mammalian macrophage. Primary drug treatment is based on antimony compounds, notably the pentavalent antimonials sodium stibogluconate and N-methylglucamine antimonate. These must be given in daily intramuscular doses for several weeks; they entail unpleasant side effects and are not very effective against cutaneous leishmaniasis. The only immunisation strategy against leishmaniasis used so far with any success in man has been restricted to the cutaneous diseases. It is based on convalescent immunity following controlled induction of a lesion with viable L. major (GREENBLATT 1980). The feasibility of vaccination with killed vaccines is currently being evaluated.

Keywords

Sugar Interferon Cyclosporin Arena Antimony 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arthur RP, Mason D (1986) T cells that help B cell responses to soluble antigen are distinguishable from those producing interleukin 2 on mitogenic or allogeneic stimulation. J Exp Med 163: 774–786.PubMedCrossRefGoogle Scholar
  2. Behforouz NC, Wenger CD, Mathison BA (1986) Prophylactic treatment of BALB/c mice with cyclosporine A and its analog B-5-49 enhances resistance to Leishmania major. J Immunol 136: 3067–3075.PubMedGoogle Scholar
  3. Blackwell JM (1983) Leishmania donovani infection in heterozygous and recombinant H-2 haplotype mice. Immunogenetics 18: 101–109.PubMedCrossRefGoogle Scholar
  4. Blackwell JM, Roberts MB, Alexander J (1985a) Response of BALB/c mice to leishmanial infection. Curr Top Microbiol Immunol 122: 97–106.PubMedCrossRefGoogle Scholar
  5. Blackwell JM, Hale C, Roberts MB, Ulczak OM, Liew FY, Howard JG (1985b) An H-l1-linked gene has a parallel effect on Leishmania major and Leshmania donovani infections in mice. Immunogenetics 21: 385–395.PubMedCrossRefGoogle Scholar
  6. Bottomly K (1988) A functional dichotomy in CD4+ T lymphocytes. Immunol Today 9: 268–274.PubMedCrossRefGoogle Scholar
  7. Bradley DJ (1977) Regulation of Leishmania populations within the host. II. Genetic control of acute susceptibility of mice to Leishmania donovani infection. Clin Exp Immunol 30: 130–140.PubMedGoogle Scholar
  8. Button LL, McMaster WR (1988) Molecular cloning of the major surface antigen of Leishmania. J Exp Med 167: 724–729.PubMedCrossRefGoogle Scholar
  9. Carvalho EM, Teixeira R, Johnson WD (1981) Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infect Immun 33: 498–503.PubMedGoogle Scholar
  10. Ciliari E, Liew FY, Lelchuk R (1986) Suppression of interleukin-2 production by macrophages in susceptible BALB/c mice infected with Leishmania major. Infect Immun 54: 386–394.Google Scholar
  11. Cillari E, Liew FY, LoCampo P, Milano S, Mansueto S, Salerno A (1988) Suppression of IL-2 production by cryopreserved peripheral blood mononuclear cells from patients with active visceral leishmaniasis in Sicily. J Immunol 140: 2721–2726.PubMedGoogle Scholar
  12. Crocker PR, Davies EV, Blackwell JM (1987) Variable expression of the murine natural resistance gene Lsh indifferent macrophage populations infected in vitro with Leishmania donovani. Parasite Immunol 9: 705–719.PubMedCrossRefGoogle Scholar
  13. Greenblatt CL (1980) The present and future of vaccination for cutaneous Leishmaniasis. In: Mizrahi A, Hertman I, Klinberg MA (eds) New developments with human and veterinary vaccines. Liss, New York, p 259–285.Google Scholar
  14. Gorczynski RM (1985) Immunization of susceptible BALB/c mice against Leishmania braziliensis. II. Use of temperature-sensitive avirulent clones of parasite for vaccination purposes. Cell Immunol 94: 11–20.PubMedCrossRefGoogle Scholar
  15. Gorczynski RM (1986) Do sugar residues contribute to the antigenic determinants responsbile for protection and/or abolition of protection in leishmania-infected BALB/c mice? J Immunol 137: 1010–1016.PubMedGoogle Scholar
  16. Haldar JP, Ghose S, Saha KC, Ghose AC (1983) Cell-mediated immune response in Indian kala-azar and post kala azar dermal leishmaniasis. Infect Immun 42: 702–709.PubMedGoogle Scholar
  17. Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM (1989) Reciprocal expression of interferon-γ or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med 169: 59–72.PubMedCrossRefGoogle Scholar
  18. Herman R (1980) Cytophilic and opsonic antibodies in visceral leishmaniasis in mice. Infect Immun 28: 585–593.PubMedGoogle Scholar
  19. Ho M, Koech DK, Iha DM, Bryceson ADM (1983) Immunosuppression in Kenyan visceral leishmaniasis. Clin Exp Immunol 51: 207–214.PubMedGoogle Scholar
  20. Howard JG, Hale C, Liew FY (1980) Genetically determined susceptibility to Leishmania tropica infection is expressed by haematopoietic donor cells in mouse radiation chimaeras. Nature 288: 161–162.PubMedCrossRefGoogle Scholar
  21. Howard JG, Hale C, Liew FY (1981) Immunological regulation of experimental cutaneous leishmaniasis. IV. Prophylactic effect of sublethal irradiation as a result of abrogation of suppressor T cell generation in mice genetically susceptible to Leishmania tropica infection. J Exp Med 153: 557–568.PubMedCrossRefGoogle Scholar
  22. Howard JG, Nicklin S, Hale C, Liew FY (1982) Prophylactic immunisation against experimental leishmaniasis. I. Protection induced in mice genetically vulnerable to fatal Leishmania tropica infection. J Immunol 129: 2206–2211.PubMedGoogle Scholar
  23. Janeway CA (1975) Cellular cooperation during in vivo anti-hapten antibody response. I. The effect of cell number on the response. J Immunol 114: 1394–1401.PubMedGoogle Scholar
  24. Lelchuk R, Carrier M, Kahl L, Liew FY (1989) Distinct IL-3 activation profile induced by intravenous versus subcutaneous routes of immunisation. Cell Immunol 122: 338–349.PubMedCrossRefGoogle Scholar
  25. Lelchuk R, Gravely R, Liew FY (1988) Susceptibility to murine cutaneous leishmaniasis correlates with the capacity to generate interleukin-3 in response to leishmania antigen in vitro. Cell Immunol 111: 66–76.PubMedCrossRefGoogle Scholar
  26. Liew FY (1983) Specific suppression of responses to Leishmania tropica by a cloned T-cell line. Nature 305: 630–632.PubMedCrossRefGoogle Scholar
  27. Liew FY (1986) Cell-mediated immunity in experimental cutaneous leishmaniasis. Parasitol Today 2: 260–270.CrossRefGoogle Scholar
  28. Liew FY (1989) Functional heterogeneity of CD4+ T cells in leishmaniasis. Immunol Today 10: 40–45.PubMedCrossRefGoogle Scholar
  29. Liew FY, Dhaliwal JS (1987) Distinctive cellular immunity in genetically susceptible BALB/c mice recovered from Leishmania major infection or after subcutaneous immunisation with killed parasites. J Immunol 138: 4450–4456.PubMedGoogle Scholar
  30. Liew FY, Parish CR (1974) Lack of correlation between cell-mediated immunity to the carrier-hapten helper effect. J Exp Med 139: 779–784.PubMedCrossRefGoogle Scholar
  31. Liew FY, Hale C, Howard JG (1982) Immunologic regulation of experimental cutaneous leishmaniasis. V. Characterisation of effector and specific suppressor T cells. J Immunol 128: 1917–1922.PubMedGoogle Scholar
  32. Liew FY, Howard JG, Hale C (1984) Prophylactic immunisation against experimental leishmaniasis. III. Protection against fatal Leishmania tropica infection induced by irradiated promastigotes involves Lyt-l+2- T cells that do not mediate cutaneous DTH. J Immunol 132: 456–461.PubMedGoogle Scholar
  33. Liew FY, Millott S, Li Y, Lelchuk R, Chan WL, Ziltener H (1989) Macrophage activation by interferon-gamma from host-protective T-cells is inhibited by interleukin (IL) 3 and IL-4 produced by disease-promoting T-cells in Leishmaniasis. Eur J Immunol 19: 1227–1232.PubMedCrossRefGoogle Scholar
  34. Liew FY, Singleton A, Ciliari E, Howard JG (1985) Prophylactic immunisation against experimental leishmaniasis. V. Mechanism of anti-protective blocking effect induced by subcutaneous immunisation against Leishmania major infection. J Immunol 135: 2102–2107.PubMedGoogle Scholar
  35. Liew FY, Hodson K, Lelchuk R (1987) Prophylactic immunisation against experimental leishmaniasis. VI. Comparison of protective and disease-promoting T cells. J Immunol 139: 3112–3117.PubMedGoogle Scholar
  36. Louis JA, Mendonca S, Titus RG, Cerottini JC, Cerny A, Zinkernagel R, Milon G, Marchai G (1986) The role of specific T cell subpopulations in murine cutaneous leishmaniasis. In: Cinader B, Miller RG (eds) Progress in immunology. VI. Academic, New York, p 762–769.Google Scholar
  37. Marrack PC, Kappler JW (1975) Antigen-specific and non-specific mediators of T-cell/B-cell cooperation. I. Evidence for their production by different T-cells. J Immunol 114: 1116–1125.PubMedGoogle Scholar
  38. Maue J, Behin R (1982) Leishmaniasis. In: Cohen S, Warren KS (eds) Immunology of parasitic infections. Blackwell, p 299-335.Google Scholar
  39. Mitchell GF, Handman E (1985) T lymphocytes recognise Leishmania glycoconjugates. Parasitol Today 2: 61–63.CrossRefGoogle Scholar
  40. Mitchell GF, Curtis JM, Scollay RG, Handman E (1981) Resistance and abrogation of resistance to cutaneous leishmaniasis in reconstituted BALB/c nude mice. Aust J Exp Biol Med Sci 59: 539–554.PubMedCrossRefGoogle Scholar
  41. Modabber F (1987) The leishmaniasis. In: Maurice J, Pearce AM (eds) Tropical disease research, a global partnership, eighth programme report, TDR. World Health Organisation, Geneva, p 99–112.Google Scholar
  42. Morimoto C, Letvin NL, Distaso JA, Aldrich WR, Schlossman SF (1985) The isolation and characterisation of the human suppressor inducer T cell subset. J Immunol 134: 1508–1515.PubMedGoogle Scholar
  43. Mosmann TR, Coffman RL (1987) Two types of mouse helper T cell clone—implications for immune regulation. Immunol Today 8: 223–227.CrossRefGoogle Scholar
  44. Mossmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL (1986) Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136: 2348–2357.Google Scholar
  45. Parish CR, Liew FY (1972) Immune response to chemically modified flagellili. III. Enhanced cell-mediated immunity during high and low gene antibody tolerance to flagellin. J Exp Med 135: 298–311.PubMedCrossRefGoogle Scholar
  46. Pearson RD, Steigbigel RT (1980) Mechanism of lethal effect of human serum upon Leishmania donovani. J Immunol 125: 2195–2201.PubMedGoogle Scholar
  47. Petersen EA, Neva FA, Barrai A, Correa-Coronas R, Bogaert-Diaz H, Martinex D, Ward FE (1984) Monocyte suppression of antigen-specific lymphocyte responses in diffuse cutaneous leishmaniasis patients from the Dominican Republic. J Immunol 132: 2603–2608.PubMedGoogle Scholar
  48. Powrie F, Mason D (1988) Phenotypic and functional heterogeneity of CD4+ T cells. Immunol Today 9: 274–277.PubMedCrossRefGoogle Scholar
  49. Preston PM, Dumonde DC (1976) Experimental cutaneous leishmaniasis. V. Protective immunity in subclinical and self-healing infection in the mouse. Clin Exp Immunol 23: 126–138.PubMedGoogle Scholar
  50. Preston PM, Carter RL, Leuchars E, Davies AJS, Dumonde DC (1972) Experimental cutaneous leishmaniasis. III. Effects of thymectomy on the course of infection of CBA mice with Leishmania tropica. Clin Exp Immunol 10: 337–357.PubMedGoogle Scholar
  51. Reiner NE, Finke JH (1983) Interleukin 2 deficiency in murine Leishmania donovani and its relationship to depressed spleen cell responses to phytohemagglutinin. J Immunol 131: 1487–1491.PubMedGoogle Scholar
  52. Rezai HR, Ardekali SM, Amirhakimi G, Kharazmi A (1978) Immunological features of kala-azar. Am J Trop Med Hyg 27: 1079–1082.PubMedGoogle Scholar
  53. Rezai HR, Farrell J, Soulsby El (1980) Immunological responses of L. donovani infection in mice and significance of T cell in resistance to experimental leishmaniasis. Clin Exp Immunol 40: 508–514.PubMedGoogle Scholar
  54. Russell DG, Alexander J (1988) Effective immunization against cutaneous leishmaniasis with defined membrane-antigens reconstituted into liposomes. J Immunol 140: 1274–1279.PubMedGoogle Scholar
  55. Sacks DL, Scott PA, Asofsky R, Sher FA (1984) Cutaneous leishmaniasis in anti-IgM-treated mice: enhanced resistance due to functional depletion of a B cell-dependent T cell involved in the suppressor pathway. J Immunol 132: 2072–2077.PubMedGoogle Scholar
  56. Sadick MD, Locksley RM, Tubbs C, Raff HV (1986) Murine cutaneous leishmaniasis: resistance correlates with the capacity to generate interferon-γ in response to leishmania antigens in vitro. J Immunol 136: 655–661.PubMedGoogle Scholar
  57. Scott PA, Farrell JP (1981) Experimental cutaneous leishmaniasis. I. Nonspecific immunosuppression in BALB/c mice infected with Leishmania tropica. J Immunol 127: 2395–2400.PubMedGoogle Scholar
  58. Scott P, Natovitz P, Sher A (1986) B lymphocytes are required for the generation of T cells that mediate healing of cutaneous leishmaniasis. J Immunol 137: 1017–1021.PubMedGoogle Scholar
  59. Scott P, Pearce E, Natovitz P, Sher A (1987) Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes. J Immunol 139: 221–227.PubMedGoogle Scholar
  60. Scott P, Natovitz P, Coffman RL, Pearce E, Sher A (1988a) Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med 168: 1675–1684.PubMedCrossRefGoogle Scholar
  61. Scott P, Pearce E, Natovitz P, Sher A (1988b) Adoptive transfer of protective immunity against lethal Leishmania major infection with an L3T4 (Thl) T cell clone recognising a low molecular weight parasite antigen. FASEB J 2: Al256.Google Scholar
  62. Silver J, Benacerraf B (1974) Dissociation of T cell helper function and delayed hypersensitivity. J Immunol 113: 1872–1875.PubMedGoogle Scholar
  63. Solbach W, Forberg K, Kammerer E, Bogdan C, Rollinghoff M (1986) Suppressive effect of cyclosporin A on the development of Leishmania tropica-induced lesions in genetically susceptible BALB/c mice J. Immunol 137: 702–707.Google Scholar
  64. Sterm JJ, Oca MJ, Rublin BY, Anderson SL, Murray HW (1988) Role of L3T4+ and Lyt-2+ cells in experimental visceral leishmaniasis. J Immunol 140: 3971–3977.Google Scholar
  65. Titus RG, Lima GC, Engers HD, Louis JA (1984) Exacerbation of murine cutaneous leishmaniasis by adoptive transfer of parasite-specific helper T cell populations capable of mediating Leishmania major-specific delayed-type hypersensitivity. J Immunol 133: 1594–1600.PubMedGoogle Scholar
  66. Titus RG, Ceredig R, Cerottini JC, Louis JA (1985) Therapeutic effect of anti-L3T4 monoclonal antibody GK 1.5 on cutaneous leishmaniasis in genetically susceptible BALB/c mice. J Immunol 135: 2108–2114.PubMedGoogle Scholar
  67. Titus RG, Milon G, Marchai G, Vassalli P, Cerottini J-C, Louis J (1987) Involvement of specific Lyt-2+ T cells in the immunological control of experimentally induced murine cutaneous leishmaniasis. Eur J Immunol 17: 1429–1433.PubMedCrossRefGoogle Scholar
  68. Titus R, Kinsey P, Thoedos C, Louis J (1988) Induction of resistance to experimental cutaneous leishmaniasis in genetically-susceptible BALB/c mice by immunisation with chemically-mutagenised non-infective clones of Leishmania major. FASEB J 2: A887.Google Scholar
  69. Wallis AE, McMaster WR (1987) Identification of Leishmania Genes encoding proteins containing tandemly repeating peptides. J Exp Med 166: 724–729.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • F. Y. Liew
    • 1
  1. 1.Department of Experimental ImmunobiologyWellcome Research LaboratoriesBeckenham, KentUK

Personalised recommendations